Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.

You may also be interested in...



Deals Of The Week: Pfizer Management Updates Thoughts On Split

Pfizer top management hasn’t yet decided whether it will divide in two or stop at a “virtual split.” Plus updates on Lundbeck/Otsuka, Shire/SARcode, AstraZeneca/Actavis, and more.

Actos To Get Bladder Cancer Warnings In Europe And A Chance At A Rebound

EU's top scientific advisory panel says Takeda's diabetes drug should have new contraindications and warnings about bladder cancer added to its prescribing information.

Actos To Get Bladder Cancer Warnings In Europe And A Chance At A Rebound

EU's top scientific advisory panel says Takeda's diabetes drug should have new contraindications and warnings about bladder cancer added to its prescribing information.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel